Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers

Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers

Abstract Background Whether human T-lymphotropic virus type 1 (HTLV-1) carriers can develop sufficient humoral immunity after coronavirus disease 2019 (COVID-19) vaccination is unknown. Methods To investigate humoral immunity after COVID-19 vaccination in HTLV-1 carriers, a multicenter, prospective...

Full description

Bibliographic Details
Main Authors: Takuro Kameda, Atae Utsunomiya, Nobuaki Otsuka, Yoko Kubuki, Taisuke Uchida, Kotaro Shide, Ayako Kamiunten, Nobuaki Nakano, Masahito Tokunaga, Takayoshi Miyazono, Yoshikiyo Ito, Kentaro Yonekura, Toshiro Kawakita, Keiichi Akizuki, Yuki Tahira, Masayoshi Karasawa, Tomonori Hidaka, Ayaka Konagata, Norifumi Taniguchi, Yuma Nagatomo, Fumiko Kogo, Koichiro Shimizu, Hiroaki Ueno, Junzo Ishizaki, Naoya Takahashi, Yoshihiko Ikei, Michihiro Hidaka, Hideki Yamaguchi, Kazuya Shimoda
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Infectious Diseases
Subjects:
COVID-19
HTLV-1
SARS-COV-2 spike protein
Humoral immunity
Vaccination
Online Access:https://doi.org/10.1186/s12879-024-09001-z

Internet

https://doi.org/10.1186/s12879-024-09001-z

Similar Items